Shire receives FDA approval for Mydayis to treat attention deficit hyperactivity disorder

Biotechnology company Shire has received the US Food and Drug Administration (FDA) approval for Mydayis (mixed salts of a single-entity amphetamine product) for the treatment of attention deficit hyperactivity disorder (ADHD).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news